Therapeutic anti-tumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

PURPOSE: Eradication of post-treatment residual myeloma cells is needed to prevent relapses and immunostimulatory monoclonal antibodies (mAbs) such as anti-CD137, CTLA-4, CD40, etc, that enhance the immune response against malignancies represent a means of achieving this purpose. This study explores...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Murillo, Oihana, Arina, Ainhoa, Hervas-Stubbs, Sandra, Gupta, Anjana, McCluskey, Brandon, Dubrot, Juan, Palazón, Asís, Azpilikueta, Arantza, Ochoa, Maria C., Alfaro, Carlos, Solano, Sarai, Pérez-Gracia, José L., Oyajobi, Babatunde O., Melero, Ignacio
Formato: Artigo
Idioma:Inglês
Publicado: 2008
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2583963/
https://ncbi.nlm.nih.gov/pubmed/18980984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0285
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares